A biomimetic delivery strategy for transforming growth factor beta (TGF-β) is described, in which TGF-β is presented in a latent form (the small latent complex, SLC), which is inactive until modified by the actions of the cells. In this work, SLC is tethered to a hyaluronic acid hydrogel scaffold to enhance in vitro chondrogenesis.
No takes yet. Share an insight, caveat, or question.
Place et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: